ApoA-I Mimetics

Esperion’s management team has had previous success in the identification and clinical development of synthetic ApoA-I therapies.

In June 2011, we acquired the exclusive worldwide rights to 4WF from the Cleveland Clinic Foundation. 4WF is a next-generation injectable, synthetic ApoA-I therapy.

We are currently evaluating 4WF in pre-clinical studies and may advance the development of this agent to reverse the deleterious effects of atherosclerosis.